Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rolapitant - GlaxoSmithKline

Next Previous
X
Search
Drug Profile

Rolapitant - GlaxoSmithKline

Alternative Names: Rolapitant hydrochloride; SCH-619734; VARUBI; Varuby

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer GSK; Merck & Co; Schering-Plough
  • Class Antiemetics; Ethers; Piperidines; Pyrrolidines; Small molecules; Spiro compounds
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting
  • Discontinued Cough; Postoperative nausea and vomiting

Most Recent Events

  • 30 Jul 2020 Tesaro in collaboration with Duke University reinitiates the phase II trial for Chemotherapy induced nausea and vomiting (Combination therapy, Prevention) in USA (NCT02991456)
  • 22 Apr 2020 Tesaro in collaboration with Duke University suspends patient enrollments in the phase II trial for Chemotherapy induced nausea and vomiting (Combination therapy, Prevention), due to COVID-19 restrictions, in USA(NCT02991456)
  • 22 Jan 2019 TESARO has been acquired and merged into GlaxoSmithKline

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top